Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Cancer Res. 2014 Nov 1;74(21):5978-88. doi: 10.1158/0008-5472.CAN-14-1606. Epub 2014 Sep 12.
Cancer evolution is a process that is still poorly understood because of the lack of versatile in vivo longitudinal studies. By generating murine non-small cell lung cancer (NSCLC) orthoallobanks and paired primary cell lines, we provide a detailed description of an in vivo, time-dependent cancer malignization process. We identify the acquisition of metastatic dissemination potential, the selection of co-driver mutations, and the appearance of naturally occurring intratumor heterogeneity, thus recapitulating the stochastic nature of human cancer development. This approach combines the robustness of genetically engineered cancer models with the flexibility of allograft methodology. We have applied this tool for the preclinical evaluation of therapeutic approaches. This system can be implemented to improve the design of future treatments for patients with NSCLC.
癌症演进是一个仍未被充分了解的过程,这是由于缺乏多功能的体内纵向研究。通过生成鼠类非小细胞肺癌(NSCLC)异体移植库和配对的原代细胞系,我们详细描述了一个体内、随时间变化的癌症恶性演进过程。我们鉴定了获得转移扩散潜能、选择共同驱动突变,以及自然发生的肿瘤内异质性的出现,从而再现了人类癌症发展的随机性。这种方法将基因工程癌症模型的稳健性与同种异体移植方法的灵活性相结合。我们已经将这种工具应用于治疗方法的临床前评估。该系统可用于改进 NSCLC 患者的未来治疗方案设计。